114 related articles for article (PubMed ID: 38724281)
1. Prognostic Value of [
Caobelli F; Gözlügöl N; Bakula A; Rominger A; Schepers R; Stortecky S; Hunziker Munsch L; Dobner S; Gräni C
J Nucl Med; 2024 Jun; 65(6):944-951. PubMed ID: 38724281
[TBL] [Abstract][Full Text] [Related]
2. Quantitative
Caobelli F; Braun M; Haaf P; Wild D; Zellweger MJ
J Nucl Cardiol; 2020 Oct; 27(5):1456-1463. PubMed ID: 31538322
[TBL] [Abstract][Full Text] [Related]
3. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis.
Rapezzi C; Quarta CC; Guidalotti PL; Pettinato C; Fanti S; Leone O; Ferlini A; Longhi S; Lorenzini M; Reggiani LB; Gagliardi C; Gallo P; Villani C; Salvi F
JACC Cardiovasc Imaging; 2011 Jun; 4(6):659-70. PubMed ID: 21679902
[TBL] [Abstract][Full Text] [Related]
4. Routine 4D Cardiac CT to Identify Concomitant Transthyretin Amyloid Cardiomyopathy in Older Adults with Severe Aortic Stenosis.
Bernhard B; Leib Z; Dobner S; Demirel C; Caobelli F; Rominger A; Schütze J; Grogg H; Alwan L; Spano G; Boscolo Berto M; Lanz J; Pilgrim T; Windecker S; Stortecky S; Gräni C
Radiology; 2023 Dec; 309(3):e230425. PubMed ID: 38085082
[TBL] [Abstract][Full Text] [Related]
5. Monitoring tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy.
Rettl R; Wollenweber T; Duca F; Binder C; Cherouny B; Dachs TM; Camuz Ligios L; Schrutka L; Dalos D; Beitzke D; Loewe C; Badr Eslam R; Kastner J; Hacker M; Bonderman D
Eur Heart J Cardiovasc Imaging; 2023 Jul; 24(8):1019-1030. PubMed ID: 36881774
[TBL] [Abstract][Full Text] [Related]
6. Reduction in
Rettl R; Calabretta R; Duca F; Binder C; Kronberger C; Willixhofer R; Poledniczek M; Donà C; Nitsche C; Beitzke D; Loewe C; Auer-Grumbach M; Bonderman D; Kastl S; Hengstenberg C; Badr Eslam R; Kastner J; Bergler-Klein J; Hacker M; Kammerlander A
Amyloid; 2024 Mar; 31(1):42-51. PubMed ID: 37599395
[No Abstract] [Full Text] [Related]
7. DPD Quantification in Cardiac Amyloidosis: A Novel Imaging Biomarker.
Scully PR; Morris E; Patel KP; Treibel TA; Burniston M; Klotz E; Newton JD; Sabharwal N; Kelion A; Manisty C; Kennon S; Ozkor M; Mullen M; Hartman N; Elliott PM; Pugliese F; Hawkins PN; Moon JC; Menezes LJ
JACC Cardiovasc Imaging; 2020 Jun; 13(6):1353-1363. PubMed ID: 32498921
[TBL] [Abstract][Full Text] [Related]
8. Correlation of Quantitative
Harapoz M; Evans S; Geenty P; Kwok F; Stewart G; Taylor MS; Farlow D; Thomas L
Heart Lung Circ; 2022 Jun; 31(6):804-814. PubMed ID: 35181228
[TBL] [Abstract][Full Text] [Related]
9. The Utility of
Moore PT; Burrage MK; Mackenzie E; Law WP; Korczyk D; Mollee P
Heart Lung Circ; 2017 Nov; 26(11):1183-1190. PubMed ID: 28256403
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic and prognostic value of Technetium-99m pyrophosphate uptake quantitation for transthyretin cardiac amyloidosis.
Miller RJH; Cadet S; Mah D; Pournazari P; Chan D; Fine NM; Berman DS; Slomka PJ
J Nucl Cardiol; 2021 Oct; 28(5):1835-1845. PubMed ID: 33689152
[TBL] [Abstract][Full Text] [Related]
11. (99m)Tc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis.
Pilebro B; Suhr OB; Näslund U; Westermark P; Lindqvist P; Sundström T
Ups J Med Sci; 2016; 121(1):17-24. PubMed ID: 26849806
[TBL] [Abstract][Full Text] [Related]
12. Cardiac transthyretin amyloidosis
Löfbacka V; Axelsson J; Pilebro B; Suhr OB; Lindqvist P; Sundström T
Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1822-1832. PubMed ID: 33367948
[TBL] [Abstract][Full Text] [Related]
13. Quantitative SPECT/CT parameters of myocardial
Ben-Haim S; Chicheportiche A; Goshen E; Arad M; Smekhov M; Menezes LJ; Elliott PM; O'Mahoney E; Stern E; Yuzefovich B; Bomanji JB
EJNMMI Res; 2021 Sep; 11(1):86. PubMed ID: 34487268
[TBL] [Abstract][Full Text] [Related]
14.
Tahara N; Lairez O; Endo J; Okada A; Ueda M; Ishii T; Kitano Y; Lee HE; Russo E; Kubo T
ESC Heart Fail; 2022 Feb; 9(1):251-262. PubMed ID: 34841715
[TBL] [Abstract][Full Text] [Related]
15. Native T1 and Extracellular Volume in Transthyretin Amyloidosis.
Martinez-Naharro A; Kotecha T; Norrington K; Boldrini M; Rezk T; Quarta C; Treibel TA; Whelan CJ; Knight DS; Kellman P; Ruberg FL; Gillmore JD; Moon JC; Hawkins PN; Fontana M
JACC Cardiovasc Imaging; 2019 May; 12(5):810-819. PubMed ID: 29550324
[TBL] [Abstract][Full Text] [Related]
16. Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis.
Hutt DF; Quigley AM; Page J; Hall ML; Burniston M; Gopaul D; Lane T; Whelan CJ; Lachmann HJ; Gillmore JD; Hawkins PN; Wechalekar AD
Eur Heart J Cardiovasc Imaging; 2014 Nov; 15(11):1289-98. PubMed ID: 24939945
[TBL] [Abstract][Full Text] [Related]
17. Quantitation of
Ross JC; Hutt DF; Burniston M; Page J; Steeden JA; Gillmore JD; Wechalekar AD; Hawkins PN; Fontana M
Amyloid; 2018 Sep; 25(3):203-210. PubMed ID: 30486686
[TBL] [Abstract][Full Text] [Related]
18. Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid.
Hutt DF; Fontana M; Burniston M; Quigley AM; Petrie A; Ross JC; Page J; Martinez-Naharro A; Wechalekar AD; Lachmann HJ; Quarta CC; Rezk T; Mahmood S; Sachchithanantham S; Youngstein T; Whelan CJ; Lane T; Gilbertson JA; Rowczenio D; Hawkins PN; Gillmore JD
Eur Heart J Cardiovasc Imaging; 2017 Dec; 18(12):1344-1350. PubMed ID: 28159995
[TBL] [Abstract][Full Text] [Related]
19. Transthyretin amyloid cardiomyopathy disease burden quantified using
Watanabe S; Nakajima K; Toshima F; Wakabayashi H; Yoshida S; Yoneyama H; Komatsu J; Konishi T; Kinuya S
J Nucl Cardiol; 2023 Dec; 30(6):2721-2735. PubMed ID: 37605060
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic and prognostic contribution of DPD scintigraphy in transthyretin V30M cardiac amyloidosis.
Azevedo Coutinho MC; Cortez-Dias N; Cantinho G; Gonçalves S; Cunha N; Rodrigues T; Santos L; Conceição I; Agostinho J; Pinto FJ
Amyloid; 2024 Mar; 31(1):32-41. PubMed ID: 37493395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
